#Leukemia #ALL #Oncology #Chemotherapy #Immunotherapy #Innovation
Acute lymphoblastic leukemia (ALL) is the most common pediatric cancer, accounting for 75% of
childhood leukemias. It is characterized by excessive proliferation of immature
cells in the bone marrow, preventing normal blood cell production and leading
to fatigue, recurrent infections, and abnormal bleeding.
Thanks to advances in
chemotherapy, targeted therapies, and
immunotherapies, the prognosis for ALL has
significantly improved. In
high-income countries, these breakthroughs have led to
survival rates exceeding
90% in children, with treatments tailored to each patient’s
genetic profile and
risk level. However, in
low-income countries, managing ALL remains complex.
Limited access to innovative treatments and medical infrastructure results in
higher relapse rates and mortality. The
lack of resources,
late diagnoses,
treatment interruptions, and
poorly managed infections further complicate the
situation. In these regions, adapting treatment protocols with
effective,
low-cost, and more accessible therapies is essential.
This study explores disparities in healthcare access and the
development of tailored solutions to optimize treatment and follow-up
for children with ALL, regardless of their healthcare setting. The goal is
to identify effective and accessible strategies and improve overall care
by considering local constraints and available resources.
Curing ALL: how far have we come?
This study examines the evolution of pediatric ALL treatment
since the 1960s, highlighting the progress made through risk stratification,
which allows treatment intensity to be adjusted based on patient profiles. The
objective is to define an optimized therapeutic strategy that can be
applied even in resource-limited countries, where access to modern
treatments remains a challenge.
The history of ALL treatment demonstrates a continuous improvement in
survival rates, driven by several major advancements:
- Optimization
of multi-agent chemotherapy, with treatments adjusted to patients' risk levels.
- Introduction
of targeted therapies and immunotherapies, offering new options for resistant forms.
- Refinement
of classification strategies, minimizing unnecessary toxicities in low-risk patients.
However, in low-resource countries, access to innovative drugs
and advanced diagnostic tools (such as minimal residual disease detection)
remains limited. Despite these challenges, well-supervised standard
chemotherapy has already shown promising results, emphasizing the
importance of adapting treatments to local contexts.
Read next: TIGIT: Brake or Springboard Against Cancer?
ALL: toward safer and more effective treatments?
Acute lymphoblastic leukemia is the most common pediatric cancer. Once fatal, it now boasts a
survival rate exceeding 90% in high-income countries, thanks to advances
in chemotherapy, targeted therapies, and immunotherapies.
Despite these achievements, many challenges remain, particularly
in low-resource settings. Additionally, treatment toxicity significantly
impacts patients' quality of life, while therapy resistance limits the
effectiveness of standard protocols.
This study examines strategies for optimizing the treatment and
management of ALL, leveraging advances in risk stratification and
innovative therapies. The goal is to reduce unnecessary toxicities,
improve the management of resistant forms, and adapt protocols for
resource-limited settings.
Thanks to therapeutic progress, ALL is now largely curable. The
priority is to minimize side effects in low-risk patients while enhancing
treatment efficacy for more aggressive forms. Expanding access to care
and developing safer, more personalized therapies are crucial for improving
survival rates and reducing long-term complications.
Read next: Transplantation and Cancer: A Life-Saving Duo?
